Study to Evaluate the Likeability, Safety, and Abuse Potential of NRP 104 in Adults With Histories of Stimulant Abuse
Information source: New River Pharmaceuticals
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Attention Deficit Disorder With Hyperactivity; Amphetamine-Related Disorders; Substance-Related Disorders
Intervention: NRP104 (Drug)
Phase: Phase 1/Phase 2
Sponsored by: New River Pharmaceuticals
Official(s) and/or principal investigator(s):
Donald R. Jasinski, MD, Principal Investigator, Affiliation: Johns Hopkins University
This research is being done to evaluate if NRP104 is a safe drug. The other purpose is to
learn if NRP104 produces a high and any other effects like amphetamine and other stimulant
drugs that are abused. This information will give some indication if NRP104 can be abused.
NRP104 is an investigational drug. This means that it has not been approved by the U. S. Food
and Drug Administration (FDA). Healthy people, between the ages of 18 and 55 with histories
of substance abuse that include stimulant drugs, may join. Amphetamines are drugs that are
used most often to treat attention deficit hyperactivity disorder (ADHD) in children, to
treat narcolepsy (excessive sleepiness) and for weight loss.
Official title: A Double-Blind, Randomized, Placebo and Active-Controlled, Six-Period Crossover Study to Evaluate the Likeability, Safety, and Abuse Liability of NRP104 in Healthy Adult Volunteers With Histories of Stimulant Abuse
Study design: Treatment, Randomized, Double-Blind, Dose Comparison, Crossover Assignment, Pharmacodynamics Study
Primary outcome: The difference in the time to maximum change from baseline in the Liking scale score (Question 2) from the Drug Rating Questionnaire - Subject (DRQS).
Maximum Liking score (Question 2 from DRQS) change from baseline
Question 1 and 3 from the DRQS
Question 1, 2 and 3 from the Drug Rating Questionnaire- Observer (DRQO)
Subscale of the ARCI (MBG, Amphetamine, BG, LSD and PCAG) (subject)
Street Value assessment Questionnaire (subject)
Treatment Enjoyment assessment Questionnaire (TEAQ) (subject)
Adverse events, laboratory tests, physical examination, vital signs and ECG will be collected to
assess the safety and tolerability of NRP104.
There is a need for a less abusable stimulant medication that can provide symptom control for
children with ADHD as compared to the conventional stimulant products.
Currently, the top line amphetamine product Adderall XR(R) for the treatment of children with
ADHD involves a once-a-day morning dosing of up to 30 mg per day per Adderall XR(R) Package
Insert. Adderall XR(R) has potential for abuse and is hence is classified as a schedule II
As part of the development of NRP104 for treatment of children with ADHD, it is important to
evaluate the abuse potential of NRP104 in comparison to immediate release d-amphetamine. A
previous exploratory dose ranging study (NRP104. A01) with NRP104 demonstrated that doses of
NRP104 up to 150 mg are safe and produce effects equal to or less than 40 mg of immediate
release d-amphetamine. When compared with those of d-amphetamine, diethylproion produced
effects qualitatively similar to those of d-amphetamine but were significantly less potent.
Intravenous and subcutaneous routes diethylpropion was less potent as compared to oral route
(Jasinski et al; 1974). This larger study is designed to compare the abuse potential of
NRP104 with the Schedule II d-amphetamine sulfate and the Schedule IV diethylpropion
hydrochloride. Data collected from this study will be used to evaluate the abuse potential
Minimum age: 18 Years.
Maximum age: 55 Years.
- Male or female subject is 18 to 55 years of age, inclusive.
- Except for women who are post menopausal or surgically sterile, all female subjects
must have a negative urine pregnancy test at screening and at admission. They must
abstain from sexual activity, or use acceptable contraceptives throughout the study,
and for 30 days after the last dose of study drug. Acceptable contraceptives include
double barrier method (such as condom with spermicidal gel or diaphragm with
spermicidal gel), IUDs and hormonal contraceptives which must be pharmacologically
effective prior to study drug exposure.
- Meet DSM-IV criteria for the diagnosis of substance abuse.
- Subject must be in good health and have venous access sufficient for blood collection,
as determined by medical history, physical exam, and clinical labs.
- Agree to be admitted to the inpatient research unit for a minimum of 14 days, and will
be able to complete all protocol-specified assessments.
- Able to understand that they can withdraw from the study at any time.
- Minimum reading level of Grade Six as determined by the REALM test, at the
- Subject must voluntarily consent to participate in this study.
- Able to swallow the study medication whole.
- History of clinically significant gastrointestinal, renal, hepatic, endocrine,
oncologic, hematologic, neurologic, psychologic, immunologic or pulmonary disorders;
or cardiovascular disease, tuberculosis, epilepsy, diabetes, psychosis, glaucoma, or
any condition which in the opinion of the Investigator would jeopardize the safety of
the subject or impact study results or prevent the subject from completing the study.
- Presence or history of any medically diagnosed, clinically significant Axis I
psychiatric disorders other than substance abuse (including bipolar disorder, any
psychotic disorder, and Tourette's disorder or family history of Tourette's).
- Serious suicidal risk determined by the investigator.
- Presence of a severe learning difficulty or mental retardation, or any condition that
would interfere with participation or completion of the study.
- History of allergic or adverse response or hypersensitivity to d-amphetamine or
- Participation in a previous clinical trial within 30 days prior to study initiation.
- Blood loss, donation of one pint or more, or plasma donation within 60 days prior to
- Clinically significant abnormalities at screening or admission on results of ECG or
lab tests, including lab deviations requiring acute medical intervention or further
- Treated with a monoamine oxidase inhibitor, currently or within 13 days of initiation
of the study medication.
- Require any of the following medications: clonidine or other alpha-2 adrenergic
receptor agonists, tricyclic antidepressants, selective serotonin reuptake inhibitors
(SSRIs) theophylline, coumarin anticoagulants, or anticonvulsants; or have taken an
SSRI in the 35 days before initiation of the study medication.
- Currently physically dependent on benzodiazepines as determined by clinical evaluation
and/or urine drug screen at screening.
- Currently physically dependent on opiates as determined by naloxone challenge.
- Currently physically dependent on alcohol as determined by clinical evaluation or has
a confirmed positive Breathalyzer test at screening or admission.
- Preexisting severe gastrointestinal narrowing.
- Use of any prescription medications (except birth control) within 14 days of
admission, or will require any prescription medications, or any over-the-counter (OTC)
medications (other than acetaminophen), or herbal supplements or vitamins during the
- Positive urine pregnancy test at screening or admission.
- Female subject is pregnant or lactating.
- Related to any person directly or indirectly involved with the conduct of the study or
currently participating in the study.
Locations and Contacts
Johns Hopkins Bayview Medical Center, Clinical Studies Program, Baltimore, Maryland 21224, United States
Starting date: January 2006
Ending date: May 2006
Last updated: November 1, 2007